Yuichi Mushimoto

Dr. Yuichi Mushimoto

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
YUYASUSHI UEYANAGI
YASUSHI UEYANAGI
DSDaiki Setoyama
Daiki Setoyama
DKDaisuke Kawakami
Daisuke Kawakami
YMYuichi Mushimoto
Yuichi Mushimoto
SMShinya Matsumoto
Shinya Matsumoto
DKDongchon Kang
Dongchon Kang
Gas chromatography-mass spectrometry has been widely used to analyze hundreds of organic acids in urine to provide a diagnostic basis for organic acidemia. However, it is difficult to operate in clinical laboratories on a daily basis due to sample pretreatment processing. Therefore, we aimed to develop a fully automated system for quantifying serum organic acids using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The pretreatment CLAM-2030 device was connected to an LC-MS/MS system for processing serum under optimized conditions, which included derivatizing serum organic acids using 3-Nitrophenylhydrazine. The derivatized organic acids were separated on a reverse-phase Sceptor HD-C column and detected using negative-ion electrospray ionization multiple reaction monitoring MS. The automated pretreatment-LC-MS/MS system processed serum in less than 1 h and analyzed 19 serum organic acids, which are used to detect organic acidemias. The system exhibited high quantitative sensitivity ranging from approximately 2 to 100 µM with a measurement reproducibility of 10.4% CV. Moreover, a proof-of-concept validation of the system was performed using sera from patients with propionic acidemia (n = 5), methylmalonic acidemia (n = 2), and 3-methylcrotonylglycinuria (n = 1). The levels of marker organic acids specific to each disease were significantly elevated in the sera of the patients compared to those in control samples. The automated pretreatment-LC-MS/MS system can be used as a rapid in-hospital system to measure organic acid levels in serum for the diagnosis of organic acidemias.

Verified
Journal Article
Open access
PDF file
VTVlad Tocan
Vlad Tocan
AUAkari Utsunomiya
Akari Utsunomiya
YSYuri Sonoda
Yuri Sonoda
WMWakato Matsuoka
Wakato Matsuoka
SMSoichi Mizuguchi
Soichi Mizuguchi
SOShouichi Ohga
Shouichi Ohga
Severe obesity in young children prompts for a differential diagnosis that includes syndromic conditions. Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) syndrome is a potentially fatal disorder characterized by rapid-onset obesity associated with hypoventilation, neural crest tumors, and endocrine and behavioral abnormalities. The etiology of ROHHAD syndrome remains to be established, but recent research has been focusing on autoimmunity. We report on a 2-year-old girl with rapid-onset obesity during the first year of life who progressed to hypoventilation and encephalitis in less than four months since the start of accelerated weight gain. The patient had a high titer of anti-ZSCAN1 antibodies (348; reference range < 40), and the increased values did not decline after acute phase treatment. Other encephalitis-related antibodies, such as the anti-NDMA antibody, were not detected. The rapid progression from obesity onset to central hypoventilation with encephalitis warns about the severe consequences of early-onset ROHHAD syndrome. These data indicate that serial measurements of anti-ZSCAN1 antibodies might be useful for the diagnosis and estimation of disease severity. Further research is needed to determine whether it can predict the clinical course of ROHHAD syndrome and whether there is any difference in antibody production between patients with and without tumors.

19 March 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
YUYASUSHI UEYANAGI
YASUSHI UEYANAGI
DSDaiki Setoyama
Daiki Setoyama
TNTsuyoshi Nakanishi
Tsuyoshi Nakanishi
YMYuichi Mushimoto
Yuichi Mushimoto
VTVlad Tocan
Vlad Tocan
YKYuya Kunisaki
Yuya Kunisaki
Background/Objectives: Conventional diagnosis of inborn errors of metabolism (IEMs) requires multiple specimen types—urine organic acids, plasma amino acids, and serum acylcarnitines—analyzed on distinct analytical platforms. This multi-assay approach is labor-intensive and limits timely clinical decision making. We aimed to develop a fully automated serum-based LC–MS/MS platform for integrated quantitative metabolite profiling and to establish pediatric reference intervals (RIs) to support diagnostic interpretation. Methods: A fully automated LC–MS/MS system integrated with the CLAM-2030 automated pretreatment module was developed to enable simultaneous quantification of 25 organic acids, 8 amino acids, and 21 acylcarnitines. Analytical performance was assessed for linearity, limits of detection and quantification, precision and accuracy. Serum samples from 296 non-IEM children aged 0–6 years were analyzed to establish pediatric RIs using Box–Cox transformation and Gaussian modeling. Clinical utility was evaluated in sera from 89 patients diagnosed with IEM using z-score-based logistic regression models. Results: The method demonstrated excellent performance, with linearity (r2 > 0.99) across calibration ranges, limits of detection and quantification defined by signal-to-noise ratios > 3 and >10, and intra- and inter-assay precision < 15% CV for all 54 analytes. Twenty-one analytes met the acceptance criterion of ±20% accuracy at all quality-control levels. Pediatric RIs provided a quantitative framework for interpreting the metabolic abnormalities. In IEM patients, disease-specific metabolites were consistently outside the established ranges, and z-score-based logistic regression models successfully distinguished major IEM categories, including organic acidemias and long-chain fatty acid oxidation disorders. Conclusions: This fully automated, serum-based LC–MS/MS platform provides a clinically practical and quantitative framework for integrated metabolic profiling using pediatric RIs, supporting diagnosis and monitoring of IEMs in pediatric settings.

26 September 2023 in Early Human Development
Verified
Journal Article
Closed access
JFJunko Fujiyoshi
Junko Fujiyoshi
HIHirosuke Inoue
Hirosuke Inoue
TSToru Sawano
Toru Sawano
YMYuichi Mushimoto
Yuichi Mushimoto
YMYoshitomo Motomura
Yoshitomo Motomura
SOShouichi Ohga
Shouichi Ohga

20 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YKYuya Kinoshita
Yuya Kinoshita
JKJun-ichi Kido
Jun-ichi Kido
TSTakaaki Sawada
Takaaki Sawada
KSKeishin Sugawara
Keishin Sugawara
SYShinichiro Yoshida
Shinichiro Yoshida
KNKimitoshi Nakamura
Kimitoshi Nakamura
BackgroundPompe disease (PD), a lysosomal storage disorder, is caused by acid α-glucosidase (GAA) deficiency. Newborn screening (NBS) enables early PD diagnosis and enzyme replacement therapy (ERT) initiation, particularly in infantile-onset Pompe disease (IOPD). However, the clinical significance of GAA variants identified by NBS remains uncertain because of limited long-term follow-up data.MethodsBetween April 2013 and March 2025, 492,091 newborns in the Kumamoto and Fukuoka prefectures of Japan underwent PD NBS using dried blood spot-based GAA assays. The screening protocol was sequentially optimized using three assay methods (Methods I, II, and III). Newborns with persistently low GAA activity underwent clinical evaluations and were offered GAA gene sequencing. Long-term clinical follow-up data of screening-positive individuals were retrospectively analyzed, and the clinical significance of the identified GAA variants was evaluated.ResultsA total of 492,091 newborns underwent PD-NBS between 2013–2025. The complex allele c.[752C>T;761C>T] was reclassified as nonpathogenic, further resulting in the reclassification of six individuals previously considered as potential late-onset Pompe disease (LOPD) carriers or potential carriers. Two infants with IOPD and one with potential LOPD were identified. Both patients with IOPD received early ERT with favorable systemic outcomes during follow-up, although one patient developed progressive central nervous system abnormalities. The individual classified as having potential LOPD remained clinically asymptomatic during the approximate 7-year follow-up period.ConclusionsPD NBS has enabled early the diagnosis and treatment of clinically significant PD in Japan. Long-term follow-up facilitated GAA variant re-evaluation and highlighted the potential for neurological complications despite favorable systemic ERT responses.

18 August 2026 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
NKNobuhiko Koga
Nobuhiko Koga
HYHiroaki Yodogawa
Hiroaki Yodogawa
TSTakaaki Sawada
Takaaki Sawada
YMYuichi Mushimoto
Yuichi Mushimoto
SNShinichiro Nagamitsu
Shinichiro Nagamitsu
TITakahito Inoue
Takahito Inoue
We described a 12‐year‐old boy with classic Fabry disease who was diagnosed through newborn screening. At age 6.2, he started agalsidase alfa based on evidence of subclinical organ involvement. At age 7.2, acroparesthesia subsequently developed. At age 10.9, after switching to agalsidase beta due to an insufficient clinical and biochemical response, his acroparesthesia resolved and plasma Lyso‐Gb3 decreased. This report broadens the clinical understanding of children with Fabry disease.